Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

Trump Secures Major Win as AstraZeneca Joins Pfizer in Lowering US Drug Prices

AstraZeneca joins Pfizer in cutting US drug prices under Trump's new deal to offer lower costs for Medicaid patients.

International Business Times

AstraZeneca Joins Trump's Push to Make Medicines Cheaper — But Why Are Critics Skeptical?

US President Donald Trump announced a deal with UK pharmaceutical AstraZeneca to lower certain drugs for government's Medicaid health plan.

International Business Times UK

AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs

Company will sell some medicines at a discount to government’s Medicaid health plan in exchange for tariff relief

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration

The Independent UK

Trump announces AstraZeneca will offer discount drugs on ‘TrumpRx’ website

TrumpRx.gov, a website where Americans can buy pharmaceutical drugs under President Donald Trump’s new drug pricing plan, is set to begin operation in 2026

The Independent UK

5 Healthcare Plays Powering the Sector’s Big Comeback

After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.

MarketBeat

NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump

UK ministers preparing to raise payments to end standoff with pharma industry, cited as reason for firms axing British investments

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

MarketBeat

TrumpRx Brings Pfizer Into the Green—Is It a Buy?

Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.

MarketBeat

Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal

Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.

MarketBeat

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

MarketBeat

Wall Street Hits Record Highs As Rate Cut Bets Offset Shutdown: This Week In Markets

Wall Street soared to fresh record highs at the end of the week, brushing aside the 21st U.S. government shutdown in history and a missing jobs report, as investors doubled down on bets for interest rate cuts and cheered strong gains in pharmaceutical and AI-driven tech stocks.

Benzinga

These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap

Health care stocks are on track for their best week in years, yet even after the rally, several pharma giants remain absurdly cheap by market standards.

Benzinga

TrumpRx Is Obamacare in Trump's Handwriting

Pfizer wins big in Trump’s new drug discount gimmick.

Reason

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Mark Cuban says Trump’s new drug platform could succeed if it forces pharma managers to change: ‘If that happens, Trump gets all the credit’

Cuban’s Cost Plus Drugs, which he founded in 2022, similarly provides direct-to-consumer discounted pharmaceuticals.

MarketBeat

Top 3 Dividend Achievers for October: High Yields, Growth Ahead

High-yield Dividend Achievers, such as United Parcel Service, Verizon, and Pfizer, offer attractive entry points in October for income investors.

Barchart

Stocks Rally as Weak US Jobs News Reinforces Fed Rate Cut Hopes

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +0.34%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.49%. December E-mini S&P futures (ESZ25 ) rose +0.30%, and December E-mini Nasdaq futures...

Benzinga

Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years

Investors cheered a breakthrough drug pricing agreement between President Donald Trump and Pfizer Inc. (NYSE:PFE), sparking a sector-wide surge in health care stocks that delivered the biggest rally in five years.

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Inside the TrumpRx website and its unusual launch

Trump has been urging prescription drug manufacturers to lower U.S. prices.

Benzinga

Pfizer Shares Are Trading Higher Wednesday: What's Going On?

Pfizer (NYSE:PFE) shares are trading higher Wednesday after President Donald Trump announced a drug-pricing deal with the company.

Benzinga

Eli Lilly Shares Are Trading Higher Wednesday: What's Going On?

Eli Lilly And Company (NYSE:LLY) shares are trading higher Wednesday after President Donald Trump recently announced a deal with Pfizer as well as the ‘TrumpRx’ site to decrease prices.

Benzinga

Moderna Stock Is Rallying Wednesday: What's Driving The Action?

Moderna Inc (NASDAQ:MRNA) stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector. The rally follows a landmark agreement Tuesday between Pfizer Inc (NYSE:PFE) and the Trump administration to lower prescription drug prices.

Evening Standard

FTSE 100 hits another high despite concerns over US government shutdown

Drug companies AstraZeneca, Hikma Pharmaceuticals and GSK were all big risers.

The Independent UK

How TrumpRx will work — and why insured Americans may not save any money

Pfizer will now sell drugs to Medicaid at ‘most-favored-nation’ prices, the White House announced

Benzinga

Stock Of The Day: Will Pfizer Head Higher?

Shares of Pfizer Inc. (NYSE:PFE) continue to head higher on Wednesday, a day after the company announced that it has secured a three-year grace period from President Donald Trump's tariffs on pharmaceuticals. This will enable Pfizer to offer its medication at significantly discounted prices compared to current rates.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.